NY-UNIFRAX
7.4.2021 13:02:12 CEST | Business Wire | Press release
Unifrax , the leading manufacturer of high-performance specialty materials, today introduced a new, nano-structured alumina catalyst support technology for the transportation market – Eco-lytic™ by Unifrax . Housed within a vehicle’s catalytic converter, the Eco-lytic catalyst support fiber is designed to replace the existing catalytic converter or add to existing systems in order to enhance emission reduction, consume fewer precious metals and raw materials, and drive lower energy usage through vehicle weight reduction. The solution is designed to help prolong a cleaner engine life and enable vehicle manufacturers to meet increasingly stringent environmental, social, and governance (ESG) standards and regulations, while providing considerable cost savings as the market transitions to electric vehicles (EVs).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210407005247/en/
Eco-lytic is currently in advanced testing with several global automakers. Preliminary results suggest the solution can reduce the mass of catalyst support media by up to 80 percent and lower platinum group metal loading by up to 40 percent compared to traditional systems. This results in increased efficiency due to faster light-off of catalytic performance. Unifrax will have commercial production capability on-line in late 2021.
“The transportation industry is going through an incredible transformation – vehicle manufacturers and regulators are focusing efforts on reducing greenhouse gas emissions and transitioning to electric or plug-in hybrid vehicles. This transition will not happen overnight, and the industry is in desperate need of nearer-term solutions to help bridge the sector’s transition to a greener footprint. Eco-lytic is that solution and the step change we need today,” said Chad Cannan, Senior Vice President of Research and Development, Unifrax. “Eco-lytic is poised to be a game changer for any conventional engine, large or small, mobile or stationary. Our product is designed to enhance emissions reductions, reduce the need for precious raw materials, extend cleaner engine lives and help drive a more sustainable carbon footprint through vehicle weight reduction.”
Eco-lytic’s flexible structure not only offers efficiency and cost savings benefits, it also provides transportation industry partners and manufacturers with unique packaging options. Unifrax has the ability to tailor the Eco-lytic product to meet the needs of individual partners through custom shapes and sizes to fit into locations where existing technologies cannot.
“Unifrax continues to pursue its mission to make the world a greener, cleaner, and safer place. We have been working to support the industry’s transition to EVs through a robust battery and technology solution portfolio that includes: our recently announced proprietary anode technology SiFab™, which drives significantly higher energy density in lithium ion batteries, our AGM separator materials, our large format lithium ion glass separators, our interstitial thermal runaway barriers, our battery compartment fire protection systems and now Eco-lytic,” said John Dandolph, President and CEO, Unifrax. “Eco-lytic provides an exciting bridge to reduce catalytic converter weights and costs, reduce the use of precious metals and raw materials, and minimize the environmental impact of conventional engines as the industry transitions to EVs. As such, Eco-lytic is a unique and proprietary solution which opens the door to a new age of emission control aligned with our mission at Unifrax.”
Building on Unifrax’s deep history of fiber-based technology and manufacturing, Eco-lytic is Unifrax’s first step into catalytic support. Unifrax, the inventor of specialty ceramic fibers, has a track record of 75+ years of developing and supplying engineered inorganic materials on a large scale to advanced industries worldwide, including electric vehicles, aerospace, and chemical processing.
Unifrax will be available during SAE’s WCX Digital Summit , April 13–15, 2021, to discuss the Eco-lytic technology with interested attendees. For more information on Eco-lytic, visit www.unifrax.com .
About Unifrax
Unifrax develops and manufactures high performance specialty materials used in advanced applications including high-temperature industrial insulation, electric vehicles, energy storage, filtration, and fire protection, among many others. Unifrax products are designed with the ultimate goal of saving energy, reducing pollution, and improving safety for people, buildings and equipment by delivering on our commitment to our customers of greener, cleaner, safer solutions for their application challenges. Unifrax has 37 manufacturing facilities operating in 12 countries and employs 2,700+ employees globally. More information is available at www.unifrax.com . For updates, follow us on Twitter , LinkedIn , and Facebook .
About Clearlake
Founded in 2006, Clearlake Capital Group, L.P. is an investment firm operating integrated businesses across private equity, credit and other related strategies. With a sector-focused approach, the firm seeks to partner with experienced management teams by providing patient, long term capital to dynamic businesses that can benefit from Clearlake’s operational improvement approach, O.P.S.® The firm’s core target sectors are industrials, technology, and consumer. Clearlake currently has approximately $35 billion of assets under management, and its senior investment principals have led or co-led over 300 investments. The firm has offices in Santa Monica and Dallas. More information is available at www.clearlake.com and on Twitter @ClearlakeCap .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210407005247/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom